1 Fast Tracking Orphan Drugs
event strap

An interview with Robert Meadowcroft, Muscular Dystrophy Campaign, on the new UK Early Access to Medicine Scheme

Explore whether or not the UK's Early Access to Medicines Scheme is a positive step forward

In March 2014 the UK Early Access to Medicines Scheme was launched, and within two weeks an Adaptive Licencing initiative was also launched by the European Medicines Agency (EMA). These two programmes present new opportunities to enable earlier drug access to the market, giving patients with rare diseases quicker access to potentially life saving drugs.

In this report we speak with Robert Meadowcroft, Chief Executive of the Muscular Dystrophy Campaign, about the UK Early Access to Medicines Scheme and whether or not it is a positive step forward.

Download the report now to learn more about Robert's thoughts on:

  • Whether or not the UK’s Early Access to Medicines Scheme is a positive development
  • What the government should be doing to enable those with rare diseases earlier access to medicines
  • The Muscular Dystrophy Campaign – An extra op-ed piece written by Robert


Some quick details

Email Address:*
First name:*
Last name:*
Job Title:*

Remember my details Information

Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Privacy statement »
Manage your email preferences »

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.